Login
From:
Cancer Network
(Uncensored)
subscribe
FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications
https://www.cancernetwork.com/view/fda-limits-pembrolizumab-nivolumab-in-pd-l1-low-gastric-cancer-indications
links
backlinks
Tagged with:
news coverage
hanna sanoff
Roast topics
Find topics
Find it!
Subgroup analyses from the phase 3 CheckMate649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.
